



Press Release June 3, 2015

Genovis to present data from mAbCHECK™ system on ASMS June 4.

Genovis will for the first time present data from the mAbCheck™ analytical platform solution at the American Society for Mass Spectrometry conference, ASMS, in St. Louis USA. The system is built on Genovis enzyme technology and Capsenze's unique liquid handling technology and integrated with state of the art mass spectrometry technology from Bruker.

The automated mAbCHECK™ technology allows researchers within the biopharma industry to rapidly obtain critical product quality data via a completely automated workflow. Researchers will no longer have to do manual sample handling, as every step will be handled automatically in very short time.

- We are excited to show data for the first time using the mAbCHECK™ technology, which utilizes our enzymes in a completely new setting. This first application proves that the system is able to rapidly generate important analytical results to our customers developing monoclonal antibodies for therapeutic use. The mAbCHECK platform will help us expand our customer base and the use of our enzyme within biopharma process development. We plan to accelerate the development of this technology and start beta testing together with customers this fall, says Fredrik Olsson, CEO of Genovis.

For additional information:

Fredrik Olsson, CEO Genovis AB
Phone: +46 (0)46-10 12 33
Email: fredrik.olsson@genovis.com

Additional information about mAbCHECK:

The mAbCHECK system is designed to sample a bioreactor and automatically digest and separate individual antibody subdomains for direct analysis by mass spectrometry or other technologies. The system is built on the VersAFLo liquid handling system from Capsenze adapted for use with Genovis enzyme. The first data presented at ASMS will show rapid glycan analysis of monoclonal antibodies and Fc-fusions proteins using Bruker UHR MaXis Mass Spectrometry. Glycan pattern is an important quality attribute that developers and producers of therapeutic antibodies need to monitor.

ABOUT GENOVIS (Nasdaq First North: GENO)

Genovis' business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the wholly owned subsidiaries Genovis Inc. (US) and GeccoDots AB. Genovis develops and sells unique enzymes in innovative product formats that facilitate development and quality control of biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. *Certified Advisor: Consensus t: +46(0) 31 745 50 00*

ABOUT BRUKER CORPORATION (NASDAQ: BRKR)

For more than 50 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific research instruments and high-value analytical solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.

In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics. For more information, please visit: <http://www.bruker.com>.

Media Contact:

Tony Lewtas
Bruker Daltonics Division
T: +1 978 663 3660 ext.1212
E: tony.lewtas@bruker.com

Investor Contact:

Joshua Young
Vice President of Investor Relations, Bruker Corporation
T: +1 978 663 3660 ext.1479
E: joshua.young@bruker.com